A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions

Alzheimer's DiseaseHuntington's Disease

Interventions

DRUG

Dimebon

dose escalation of single oral doses of 5, 10 and 20 mg

DRUG

Dimebon

dose escalation of single oral doses of 5, 10 and 20 mg

DRUG

Dimebon

10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days

DRUG

Dimebon

10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days

Trial Locations (1)

Pfizer Investigational Site, Glendale